Alnylam Pharmaceuticals ALNY Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Alnylam Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's current ratio?
- Alnylam Pharmaceuticals (ALNY) reported current ratio of 3.1× in Q1 2026.
- How has Alnylam Pharmaceuticals's current ratio changed year-over-year?
- Alnylam Pharmaceuticals's current ratio increased by 2.9% year-over-year, from 3× to 3.1×.
- What is the long-term trend for Alnylam Pharmaceuticals's current ratio?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's current ratio has grown at a -11.7% compound annual growth rate (CAGR), from 18.3× to 11.1×.
- What does current ratio mean?
- Whether the company has enough short-term assets to cover its short-term bills.
- How do you interpret current ratio?
- Above 1.0 means short-term assets cover short-term liabilities. Very high values can signal idle cash or bloated inventory/receivables rather than strength — there's a healthy middle, not 'more is better'.
- How does current ratio compare across companies?
- Comparable within an industry. Working-capital-light businesses can operate safely below 1.0 by collecting before they pay.